Torrent Pharmaceuticals stock
Price history
+26.01% over the period1 year: from ₹3,721.40 (November 20, 2025) to ₹4,689.50 (November 20, 2026), +26.01%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | ₹4,689.50 |
| October 30, 2026 | ₹4,613.40 |
| September 30, 2026 | ₹4,800.00 |
| August 31, 2026 | ₹5,066.00 |
| July 31, 2026 | ₹5,122.80 |
| June 30, 2026 | ₹4,620.10 |
| May 29, 2026 | ₹4,410.80 |
| April 30, 2026 | ₹4,185.10 |
| March 30, 2026 | ₹4,220.20 |
| February 27, 2026 | ₹4,333.30 |
| January 30, 2026 | ₹3,960.80 |
| December 31, 2025 | ₹3,850.00 |
| November 28, 2025 | ₹3,720.60 |
| November 20, 2025 | ₹3,721.40 |
At a glance
The company
Research, develop, manufacture, market and distribute branded and generic pharmaceutical formulations across multiple therapeutic areas
Latest results
Quarter to September 30, 2026 · EPS ₹14.23 (estimate ₹16.08)
TickerLandia's take on Torrent Pharmaceuticals
- Pricier than usual relative to earnings: P/E on the latest fiscal year 73 vs a median of 47 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 79 vs 33 (+137%) in a group of 11.
- Strong point: Market momentum (73/100 in its group). Weak point: Financial strength (26/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−10.68% from the 52-week high
Analysts · 28 analysts
Average target₹5,472.79+16.70% vs. price
Buy 23 · Hold 4 · Sell 1
TickerLandia Fingerprint: Torrent Pharmaceuticals
Compared with similar companies: very low risk and very high price.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricevery high88
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 79.2 87 Forward P/E 51.6 90 EV/EBITDA 33.2 88 Price/book 9.70 86 Price/sales 10.3 88 Profitabilityhigh60
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 22.2% 58 Gross margin 75.9% 71 ROE 15.7% 65 ROA 8.0% 63 Net margin 12.2% 45 Earnings stabilityhigh69
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.9% 75 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh68
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +13.27% 75 Revenue growth (year over year) +50.80% 93 Earnings growth (year over year) −19.50% 36 Financial strengthlow26
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.44 23 Interest coverage 8.94 35 Debt/equitycounts in reverse: lower means more financial strength 0.77 18 Current ratio 1.32 27 Dividendaverage57
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 24 years 64 Dividend yield 0.8% 24 Payout ratio 64.2% 82 Market momentumstrong73
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average +2.42% 70 1-year return +26.01% 76 Riskvery low3
How much the price swings.
Metric Value Position in group Volatility (60 days) 18.4% 4 Maximum drawdown (12 months) 11.7% 2
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Torrent Pharmaceuticals is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2026), Torrent Pharmaceuticals's P/E today is 73.4, above the median of its last 10 fiscal years (47.5; between 28.1 and 75.0 from 2017 to 2026). Torrent Pharmaceuticals's P/E (trailing 12 months): 79.2, +137% against the median of a group of 11 similar companies (33.5).
Compared with 11 similar companies
| Metric | Torrent Pharmaceuticals | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 79.2 | High | |
| Forward P/E | 51.6 | High | |
| Operating margin | 22.2% | Middle | |
| ROE | 15.7% | Middle | |
| Debt/equity | 0.77 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Torrent Pharmaceuticals. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
₹49.79B
Latest quarter · Q3 2026
Net income
₹5.34B
Latest quarter · Q3 2026
Quarterly net margin
10.7%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ₹1.78T
- P/E
- 79.2
- EPS
- ₹59.20
- Volume
- 200.04K
- Daily trading
- €14.75M
- Dividend yield
- 0.19%
- Last ex-dividend on May 29, 2026
How Torrent Pharmaceuticals is changing
All resultsRevenue grew 11.8% a year on average over the last 5 years
Operating margin rose from 22.2% to 24.6%
Profits turn into cash: free cash flow equal to 125% of net income
Returns
Torrent Pharmaceuticals returns with dividends
₹1,000 invested in Torrent Pharmaceuticals 5 years ago, on November 22, 2021, would be worth ₹3,617 today with dividends reinvested: +261.70% in total, +29.36% per year. On price alone it would be ₹3,407 (+240.66%).
| Period | Torrent Pharmaceuticals | ₹1,000 becomes |
|---|---|---|
| 1 month | +2.98% | ₹1,030 |
| 6 months | +5.88% | ₹1,059 |
| Year to date | +21.81% | ₹1,218 |
| 1 year | +27.14% | ₹1,271 |
| 3 years | +128.75% | ₹2,288 |
| 5 years | +261.70% | ₹3,617 |
| 10 years | +710.86% | ₹8,109 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Torrent Pharmaceuticals: technical analysis
Torrent Pharmaceuticals shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 8.5% below its all-time closing high (₹5,122.80, July 31, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 51
- Between 30 and 70
- vs 200-session average
- +2.42%
Support and resistance
Price areas where Torrent Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance₹5,051.57+7.72%4 touches, last on September 24, 2026
- Resistance₹4,830.44+3.01%5 touches, last on November 9, 2026
- Resistance₹4,691.33+0.04%3 touches, last on July 17, 2026
- Last price₹4,689.50
- Support₹4,473.23−4.61%3 touches, last on October 26, 2026
- Support₹4,246.43−9.45%3 touches, last on June 2, 2026
- Support₹4,095.30−12.67%4 touches, last on April 23, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 18.4%
- Largest fall in the last year
- −11.68%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Torrent Pharmaceuticals: seasonality
Average monthly price change over 32 years
Over the last 32 years, the strongest month for Torrent Pharmaceuticals has been August: +7.42% on average, positive in 19 years out of 32. The weakest has been March: −1.04% on average, positive in 16 years out of 32. November, the current month, has been positive in 20 years out of 31 (+2.48% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.06% | −2.28% | 13 of 32 |
| February | −0.22% | −1.02% | 12 of 32 |
| March | −1.04% | −1.04% | 16 of 32 |
| April | +1.90% | +3.59% | 21 of 32 |
| May | +1.78% | +0.56% | 18 of 32 |
| June | +1.88% | +2.08% | 20 of 32 |
| July | +6.32% | +7.44% | 27 of 32 |
| August | +7.42% | +1.28% | 19 of 32 |
| September | +0.71% | −1.47% | 13 of 32 |
| October | −0.31% | +1.05% | 17 of 32 |
| November | +2.48% | +1.88% | 20 of 31 |
| December | +5.40% | +5.55% | 24 of 32 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Torrent Pharmaceuticals and its competitors
Shelcal, Tedibar, Unienzyme, ProZuca and Ahaglow are among the brands under which the company sells its products. Torrent Pharmaceuticals develops, makes, markets and distributes branded and generic medicines, along with vitamin, mineral and nutrient supplements. Its range spans diabetes, cardiovascular care, the central nervous system, oncology, gastrointestinal, urology and dermatology treatments, among others. The company also offers contract manufacturing services and sells in India, the United States, Brazil, Germany, Malta and other international markets.
- Headquarters
- Ahmedabad, India
- Employees
- 18,258
- Founded
- 1959
- Chief executive
- Aman Mehta
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Torrent PharmaceuticalsTORNTPHARM | $19.25B | 22.2% | 79.2 | +5.88% |
| Shionogi4507 | $16.75B | 31.6% | 11.2 | +2.83% |
| PharmaEssentia6446 | $15.94B | 38.4% | 74.1 | +54.65% |
| Hansoh Pharmaceutical Group3692 | $23.77B | 37.3% | 25.0 | −8.51% |
| Yunnan Baiyao Group000538 | $15.07B | 11.2% | 19.4 | +11.07% |
| Laurus LabsLAURUSLABS | $14.13B | 24.1% | 97.8 | +68.58% |
Same industry or related industries, similar size. Compare Torrent Pharmaceuticals with its competitors · Full profile
